Modulating T Cell Dysfunction via IL-27 Signaling and Transcription Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for treating T cell dysfunction, such as T cell exhaustion, in chronic viral infections and cancer are limited in efficacy, as many patients do not respond to immune checkpoint blockade, highlighting the need for identifying additional co-inhibitory receptors and common triggers or regulatory mechanisms that induce and control their expression.
Innovation Solution
The discovery of IL-27 signaling as a driver of an inhibitory gene module that includes Tim-3, Lag-3, TIGIT, and IL-10, which are associated with T cell dysfunction, provides a new approach. This involves using a systems biology approach to identify key transcriptional regulators like Prdm1 and c-Maf that cooperatively drive the expression of this inhibitory gene module, and developing methods and compositions to modulate T cell dysfunction by targeting these molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint blockade (targeting PD-1 or CTLA-4) is used to treat T cell dysfunction, then some T cell responses are restored, but many patients do not respond and T cell exhaustion persists
Solution Approach 1:
The invention segments the broad category of co-inhibitory receptors into distinct targetable molecules (TIM-3, LAG-3, TIGIT, PD-1, CTLA-4) that can be addressed by separate therapeutic agents. This segmentation allows for combination therapies that simultaneously block multiple pathways, thereby improving response rates in patients who do not respond to single-agent checkpoint blockade.
Solution Approach 2:
The invention identifies a universal regulatory mechanism (IL-27 signaling through STAT1 and T-bet) that controls the expression of multiple diverse co-inhibitory receptors. By targeting this upstream universal regulator, a single therapy could potentially modulate expression across multiple checkpoint molecules, providing multi-functionality and broader therapeutic coverage.
2Reliability
If combination therapies targeting multiple co-inhibitory pathways are developed, then potency in restoring anti-tumor immunity is increased, but therapeutic complexity and potential off-target effects increase
Solution Approach 1:
The invention introduces small molecule inhibitors (e.g., RU.521, BMS-813463) as intermediary agents that can simultaneously or sequentially inhibit multiple co-inhibitory pathways. These small molecules serve as mediators that simplify the therapeutic approach compared to using multiple large molecule antibodies, while still achieving the desired multi-pathway blockade for enhanced efficacy.
3Reliability
If IL-27 signaling is blocked to reduce co-inhibitory receptor expression, then T cell dysfunction is modulated, but potential effects on other IL-27-mediated immune functions must be considered
Solution Approach 1:
The invention employs local quality by using small molecule inhibitors that can selectively target specific aspects of IL-27 signaling or downstream effectors (such as STAT1 or T-bet) rather than broadly inhibiting all IL-27 functions. This selective local inhibition allows modulation of co-inhibitory receptor expression while preserving other beneficial IL-27-mediated immune functions.
Data Source
AI summary
Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network as well as novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module. This critical molecular circuit underlies the co-expression of co-inhibitory receptors in dysfunctional T cells and identifies novel regulators of T cell dysfunction.